Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4Plasma cell 1Myeloid 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 72Paclitaxel 63Cyclophosphamide 56pembrolizumab 52Fulvestrant 42Carboplatin 39Capecitabine 37Docetaxel 32Letrozole 27Doxorubicin 23palbociclib 21pertuzumab 20Nivolumab 18eribulin 17abemaciclib 17ribociclib 16Gemcitabine 16130-nm albumin-bound paclitaxel 16durvalumab 15Everolimus 15Albumin-Bound Paclitaxel 15sacituzumab govitecan 14Lapatinib 14Filgrastim 14fludarabine 13exemestane 13Taxes 13Bevacizumab 13Cisplatin 12olaparib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × alvocidib × Breast × Clear all
NCT00020332 2013-06-17

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡